Erin Wright
Stock Analyst at Morgan Stanley
(2.95)
# 1,598
Out of 5,005 analysts
230
Total ratings
80%
Success rate
33.47%
Average return
Main Sectors:
Stocks Rated by Erin Wright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PSX Phillips 66 | Maintains: Equal-Weight | $128 → $140 | $133.01 | +5.26% | 2 | Oct 3, 2025 | |
| MCK McKesson | Maintains: Overweight | $810 → $857 | $738.06 | +16.12% | 9 | Sep 24, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $722 → $765 | $631.19 | +21.20% | 16 | Aug 15, 2025 | |
| NVST Envista Holdings | Maintains: Equal-Weight | $16 → $17 | $20.85 | -18.47% | 9 | Aug 1, 2025 | |
| CVS CVS Health | Maintains: Overweight | $80 → $82 | $77.49 | +5.82% | 5 | Aug 1, 2025 | |
| HUM Humana | Maintains: Equal-Weight | $290 → $277 | $283.72 | -2.37% | 4 | Jul 31, 2025 | |
| ALGN Align Technology | Downgrades: Equal-Weight | $249 → $154 | $132.17 | +16.52% | 23 | Jul 31, 2025 | |
| ELV Elevance Health | Maintains: Overweight | $428 → $316 | $350.50 | -9.84% | 3 | Jul 18, 2025 | |
| COR Cencora | Maintains: Equal-Weight | $313 → $330 | $302.76 | +9.00% | 1 | Jul 16, 2025 | |
| CAH Cardinal Health | Maintains: Overweight | $181 → $190 | $154.46 | +23.01% | 12 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $364 → $266 | $201.97 | +31.70% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $21 → $26 | $38.32 | -32.15% | 23 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $25 | $28.36 | -11.85% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $379 → $390 | $311.00 | +25.40% | 5 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $3.5 → $3.2 | $2.62 | +22.14% | 12 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 → $13 | $20.64 | -37.02% | 11 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $243 → $238 | $146.42 | +62.55% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $23 | $13.19 | +74.37% | 12 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $145 → $172 | $179.33 | -4.09% | 5 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $69 → $65 | $67.03 | -3.03% | 4 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $587 | $360.20 | +62.97% | 3 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $300 | $276.94 | +8.33% | 4 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $42 | $14.29 | +193.91% | 5 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $282 → $288 | $214.99 | +33.96% | 6 | Jun 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $342 → $352 | $177.33 | +98.50% | 4 | May 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $44 | $3.09 | +1,323.95% | 2 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $178 → $181 | $532.49 | -66.01% | 8 | Mar 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $17 | $53.83 | -68.42% | 6 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $104 → $121 | $37.53 | +222.41% | 7 | Jan 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $556 → $580 | $543.32 | +6.75% | 4 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $13.07 | +167.79% | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $181 → $205 | $193.89 | +5.73% | 2 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $11 | $22.78 | -51.71% | 6 | May 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $175 → $157 | $206.63 | -24.02% | 1 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $38 | $27.90 | +36.23% | 1 | May 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $31 → $17 | $4.76 | +257.14% | 1 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $300 → $308 | $504.49 | -38.95% | 1 | Oct 25, 2017 |
Phillips 66
Oct 3, 2025
Maintains: Equal-Weight
Price Target: $128 → $140
Current: $133.01
Upside: +5.26%
McKesson
Sep 24, 2025
Maintains: Overweight
Price Target: $810 → $857
Current: $738.06
Upside: +16.12%
IDEXX Laboratories
Aug 15, 2025
Maintains: Overweight
Price Target: $722 → $765
Current: $631.19
Upside: +21.20%
Envista Holdings
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $20.85
Upside: -18.47%
CVS Health
Aug 1, 2025
Maintains: Overweight
Price Target: $80 → $82
Current: $77.49
Upside: +5.82%
Humana
Jul 31, 2025
Maintains: Equal-Weight
Price Target: $290 → $277
Current: $283.72
Upside: -2.37%
Align Technology
Jul 31, 2025
Downgrades: Equal-Weight
Price Target: $249 → $154
Current: $132.17
Upside: +16.52%
Elevance Health
Jul 18, 2025
Maintains: Overweight
Price Target: $428 → $316
Current: $350.50
Upside: -9.84%
Cencora
Jul 16, 2025
Maintains: Equal-Weight
Price Target: $313 → $330
Current: $302.76
Upside: +9.00%
Cardinal Health
Jul 16, 2025
Maintains: Overweight
Price Target: $181 → $190
Current: $154.46
Upside: +23.01%
Jul 10, 2025
Downgrades: Equal-Weight
Price Target: $364 → $266
Current: $201.97
Upside: +31.70%
Jun 25, 2025
Maintains: Equal-Weight
Price Target: $21 → $26
Current: $38.32
Upside: -32.15%
May 9, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $28.36
Upside: -11.85%
May 5, 2025
Maintains: Overweight
Price Target: $379 → $390
Current: $311.00
Upside: +25.40%
Apr 17, 2025
Maintains: Underweight
Price Target: $3.5 → $3.2
Current: $2.62
Upside: +22.14%
Feb 26, 2025
Maintains: Equal-Weight
Price Target: $14 → $13
Current: $20.64
Upside: -37.02%
Feb 14, 2025
Maintains: Overweight
Price Target: $243 → $238
Current: $146.42
Upside: +62.55%
Dec 17, 2024
Maintains: Overweight
Price Target: $30 → $23
Current: $13.19
Upside: +74.37%
Dec 17, 2024
Upgrades: Overweight
Price Target: $145 → $172
Current: $179.33
Upside: -4.09%
Nov 14, 2023
Maintains: Underweight
Price Target: $69 → $65
Current: $67.03
Upside: -3.03%
Jul 14, 2023
Reiterates: Overweight
Price Target: $587
Current: $360.20
Upside: +62.97%
Aug 22, 2022
Assumes: Overweight
Price Target: $300
Current: $276.94
Upside: +8.33%
Jul 30, 2021
Maintains: Outperform
Price Target: $39 → $42
Current: $14.29
Upside: +193.91%
Jun 18, 2021
Maintains: Outperform
Price Target: $282 → $288
Current: $214.99
Upside: +33.96%
May 28, 2021
Maintains: Neutral
Price Target: $342 → $352
Current: $177.33
Upside: +98.50%
May 11, 2021
Maintains: Outperform
Price Target: $42 → $44
Current: $3.09
Upside: +1,323.95%
Mar 17, 2021
Maintains: Outperform
Price Target: $178 → $181
Current: $532.49
Upside: -66.01%
Feb 26, 2021
Maintains: Neutral
Price Target: $14 → $17
Current: $53.83
Upside: -68.42%
Jan 13, 2021
Maintains: Outperform
Price Target: $104 → $121
Current: $37.53
Upside: +222.41%
Jan 12, 2021
Maintains: Outperform
Price Target: $556 → $580
Current: $543.32
Upside: +6.75%
Jan 5, 2021
Initiates: Neutral
Price Target: $35
Current: $13.07
Upside: +167.79%
Jul 23, 2020
Maintains: Outperform
Price Target: $181 → $205
Current: $193.89
Upside: +5.73%
May 5, 2020
Maintains: Neutral
Price Target: $12 → $11
Current: $22.78
Upside: -51.71%
Apr 2, 2020
Maintains: Outperform
Price Target: $175 → $157
Current: $206.63
Upside: -24.02%
May 9, 2018
Maintains: Outperform
Price Target: $42 → $38
Current: $27.90
Upside: +36.23%
Nov 20, 2017
Maintains: Underperform
Price Target: $31 → $17
Current: $4.76
Upside: +257.14%
Oct 25, 2017
Maintains: Neutral
Price Target: $300 → $308
Current: $504.49
Upside: -38.95%